title: [Pars plana implantation of a ganciclovir drug carrier in patients with cytomegalovirus retinitis and AIDS. Indications, follow-up and postoperative complications].
abstract: We performed an open clinical trial to assess the safety and efficacy of a 1 microgram/h ganciclovir implant for the treatment of newly and pretreated cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS).
  
  
  METHODS
  Thirty-two eyes (20 patients) received the ganciclovir intraocular device and were prospectively followed up from 30 to 365 days. We used a modified technique for fixation of the device in half of the patients. The modification improved the fixation of the implant with a two-hole technique in the strut.
  
  
  RESULTS
  Thirty eyes showed stabilization of the retinitis over the time, but in two patients resistance against ganciclovir and other nucleoside analogue compounds developed. Postoperative complications included vitreous hemorrhage (n = 1), cataract (n = 1), and uveitis anterior (n = 1). Late retinal detachment was seen in five eyes (25%) at 30 to 60 days after implantation. Followup until 1 year after implantation did not show progression of CMV retinitis in 18 to 20 patients. All received antiviral CMV therapy to protect noninfected eyes and intestinum against CMV infection.
  
  
  CONCLUSIONS
  The ganciclovir intraocular device seemed to be effective in most cases of CMV retinitis and offers a promising alternative for cytomegalovirus retinitis. Patients pretreated longer than 6 months with i.v. ganciclovir have to be carefully selected for implantation, because resistance against ganciclovir could be three times more likely than in i.v.-therapy naive patients.
authors.affiliation: Abteilung Allgemeine Augenheilkunde, Johann Wolfgang Goethe-Universität Frankfurt am Main.
authors.forename: H
authors.initials: H
authors.lastname: Gümbel
authors.forename: C
authors.initials: C
authors.lastname: Rosenkranz
authors.forename: O E
authors.initials: OE
authors.lastname: Schnaudigel
authors.forename: K
authors.initials: K
authors.lastname: Mauck
authors.forename: U
authors.initials: U
authors.lastname: Fries
authors.forename: C
authors.initials: C
authors.lastname: Ohrloff
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004343:Drug Implants; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004343:Drug Implants; D015774:Ganciclovir